American Oriental Bioengineering Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

American Oriental Bioengineering, Inc.

today announced that the New York Stock Exchange has notified the Company that the Company has fallen below the NYSE's continued listing standard that requires a minimum average closing price of $1.00 per share over 30 consecutive trading days. Under NYSE rules, the Company has six months from receipt of the notice to cure the deficiency by regaining compliance with the minimum share price requirement. Subject to compliance with the NYSE's other continued listing requirements, the Company's common stock will continue to be listed and trade on the NYSE during the six month cure period.